SEC Form 4 · accession 0001209191-18-057055
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joe Newell
Officer — Chief Tech. Operations Officer
Period of report
Nov 1, 2018
Accepted (ET)
Nov 2, 2018 · 8:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 1, 2018 | M | 1,500 | $20.40 | A | 33,358 | D | |
| Common Stock | Nov 1, 2018 | S | 1,500 | $35.00 | D | 31,858 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $20.40 | Nov 1, 2018 | M | 1,500 | D | — | Apr 3, 2024 | Common Stock | 1,500 | 74,000 | D |
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018.
- F225% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service.